...
首页> 外文期刊>International Journal of Pharmacy and Pharmaceutical Sciences >INFLUENCE OF A BIOLOGICALLY ACTIVE COMPOUND FROM SUBSTITUTED THIADIAZINES ON TRANSAMINASE ACTIVITY IN MYOCARDIAL HOMOGENATE IN EXPERIMENTAL MYOCARDIAL INFARCTION
【24h】

INFLUENCE OF A BIOLOGICALLY ACTIVE COMPOUND FROM SUBSTITUTED THIADIAZINES ON TRANSAMINASE ACTIVITY IN MYOCARDIAL HOMOGENATE IN EXPERIMENTAL MYOCARDIAL INFARCTION

机译:取代的噻嗪类生物活性化合物对实验性心肌梗塞患者心肌匀浆中转氨酶活性的影响

获取原文
           

摘要

Objective : Earlier works have reported on the effectiveness of the compounds of the group of substituted 5R1, 6R2, 3,4-thiadiasine-2-amines for treating experimental myocardial infarction, conditioned by the immune-modifying action of the compound. The purpose of this study was to evaluate the action of the L17 compound of the group of substituted 5R1, 6R2, 3,4-thiadiasine-2-amines on the extent of injury and the possible recurrence of experimental myocardial infarction by the dynamic assessment of transaminase activity in blood and myocardial homogenate (tissue). Methods : Modelling of myocardial infarction in rats was performed in accordance with the author’s modification of the standard ligation model. Tissue enzyme activity of LDH and CK-MB was evaluated at days 1, 7, and 14. Results : According to the results, the decrease in LDH 1-2 activity in tissue (after experimental myocardial infarction) corresponded to the increase in enzyme activity in blood on the first day of the experiment. However, on the seventh day of the experiment, the decrease of LDH 1-2 activities in the tissue of animals treated with L17 compound corresponded with the decrease of LDH activity in blood, while in non-treated animals the relation between the enzyme levels in blood and tissue was typical for the onset of MI. Conclusions : The evaluation of enzyme levels in myocardial tissue confirms previouslyreported data that the administration of a thiadiazine compounds prevents the recurrence and decreases the size of experimental myocardial infarction. Keywords : Enzymes, L-17 compound, Myocardial infarction, Thiadiazines, Tissue enzymes.
机译:目的:较早的工作报道了取代的5R1、6R2、3,4-硫代二胺-2-胺类化合物在治疗实验性心肌梗塞中的有效性,条件是该化合物具有免疫修饰作用。这项研究的目的是通过动态评估甲氧西林对5R1、6R2、3,4-硫代二胺-2-胺类化合物中L17化合物对损伤程度和实验性心肌梗死可能复发的作用。血液和心肌匀浆(组织)中的转氨酶活性。方法:按照作者对标准结扎模型的修改,对大鼠心肌梗死进行建模。在第1、7和14天评估LDH和CK-MB的组织酶活性。结果:根据结果,组织中LDH 1-2活性的降低(实验性心肌梗塞后)与酶活性的提高相对应。实验第一天的血液中。然而,在实验的第七天,用L17化合物处理的动物的组织中LDH 1-2活性的降低与血液中LDH活性的降低相对应,而在未处理的动物中,酶水平之间的关系是血液和组织是MI发作的典型症状。结论:心肌组织中酶水平的评估证实了先前报道的数据,即噻二嗪类化合物的给药可防止复发并减小实验性心肌梗塞的大小。关键词:酶,L-17化合物,心肌梗塞,噻二嗪,组织酶。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号